CA3229079A1 - Flow through cation exchange chromatography purification processes for antibody drug conjugates - Google Patents
Flow through cation exchange chromatography purification processes for antibody drug conjugates Download PDFInfo
- Publication number
- CA3229079A1 CA3229079A1 CA3229079A CA3229079A CA3229079A1 CA 3229079 A1 CA3229079 A1 CA 3229079A1 CA 3229079 A CA3229079 A CA 3229079A CA 3229079 A CA3229079 A CA 3229079A CA 3229079 A1 CA3229079 A1 CA 3229079A1
- Authority
- CA
- Canada
- Prior art keywords
- adc
- purification
- antibody
- cys
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163236170P | 2021-08-23 | 2021-08-23 | |
| US63/236,170 | 2021-08-23 | ||
| PCT/US2022/075252 WO2023028446A1 (en) | 2021-08-23 | 2022-08-22 | Flow through cation exchange chromatography purification processes for antibody drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3229079A1 true CA3229079A1 (en) | 2023-03-02 |
Family
ID=83271094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3229079A Pending CA3229079A1 (en) | 2021-08-23 | 2022-08-22 | Flow through cation exchange chromatography purification processes for antibody drug conjugates |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240277859A1 (enExample) |
| EP (1) | EP4392433A1 (enExample) |
| JP (1) | JP2024532238A (enExample) |
| KR (1) | KR20240046733A (enExample) |
| CN (1) | CN117881686A (enExample) |
| AR (1) | AR126847A1 (enExample) |
| AU (1) | AU2022332274A1 (enExample) |
| CA (1) | CA3229079A1 (enExample) |
| IL (1) | IL310556A (enExample) |
| MX (1) | MX2024002133A (enExample) |
| TW (1) | TW202323268A (enExample) |
| WO (1) | WO2023028446A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118290513B (zh) * | 2024-06-05 | 2025-03-14 | 东曜药业有限公司 | 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1869065T3 (da) | 2005-03-11 | 2020-06-08 | Wyeth Llc | Fremgangsmåde til kromatografi med svag opdeling |
| WO2012059308A1 (en) * | 2010-11-01 | 2012-05-10 | Dsm Ip Assets B.V. | Single unit ion exchange chromatography antibody purification |
| SG10201701224UA (en) | 2012-03-12 | 2017-04-27 | Merck Patent Gmbh | Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode |
| CN104208719B (zh) * | 2014-09-24 | 2017-05-03 | 北京天广实生物技术股份有限公司 | 一种抗体偶联药物的阳离子交换层析纯化方法 |
| US20180311375A1 (en) * | 2017-04-27 | 2018-11-01 | Cadila Healthcare Limited | Process of preparing antibody-drug conjugate |
-
2022
- 2022-08-22 JP JP2024510666A patent/JP2024532238A/ja active Pending
- 2022-08-22 US US18/682,046 patent/US20240277859A1/en active Pending
- 2022-08-22 AR ARP220102261A patent/AR126847A1/es unknown
- 2022-08-22 MX MX2024002133A patent/MX2024002133A/es unknown
- 2022-08-22 CN CN202280056541.9A patent/CN117881686A/zh active Pending
- 2022-08-22 CA CA3229079A patent/CA3229079A1/en active Pending
- 2022-08-22 EP EP22768589.8A patent/EP4392433A1/en active Pending
- 2022-08-22 IL IL310556A patent/IL310556A/en unknown
- 2022-08-22 AU AU2022332274A patent/AU2022332274A1/en active Pending
- 2022-08-22 KR KR1020247006568A patent/KR20240046733A/ko active Pending
- 2022-08-22 WO PCT/US2022/075252 patent/WO2023028446A1/en not_active Ceased
- 2022-08-22 TW TW111131425A patent/TW202323268A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022332274A1 (en) | 2024-02-15 |
| MX2024002133A (es) | 2024-03-06 |
| EP4392433A1 (en) | 2024-07-03 |
| IL310556A (en) | 2024-03-01 |
| AR126847A1 (es) | 2023-11-22 |
| US20240277859A1 (en) | 2024-08-22 |
| KR20240046733A (ko) | 2024-04-09 |
| TW202323268A (zh) | 2023-06-16 |
| CN117881686A (zh) | 2024-04-12 |
| WO2023028446A1 (en) | 2023-03-02 |
| JP2024532238A (ja) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2860600C (en) | Fc-receptor based affinity chromatography | |
| JP7826243B2 (ja) | アルブミン融合タンパク質を精製する方法 | |
| CA2806314C (en) | Method for purifying active polypeptides or immunoconjugates | |
| US20140288278A1 (en) | Chromatography process for resolving heterogeneous antibody aggregates | |
| TWI625335B (zh) | 純化抗體的方法 | |
| EP2695889A1 (en) | Protein purification by ion exchange | |
| WO2011162210A1 (ja) | アミノ酸を利用したタンパク質の精製方法 | |
| Gilroy et al. | Characterization of drug load variants in a thiol linked antibody-drug conjugate using multidimensional chromatography | |
| US20240277859A1 (en) | Flow through cation exchange chromatography purification processes for antibody drug conjugates | |
| Ishihara et al. | Monoclonal antibody purification using activated carbon as a replacement for Protein A affinity chromatography | |
| US20160083453A1 (en) | Separation of recombinant polyclonal antibody multimers with minimal separation of monomers | |
| JP6116565B2 (ja) | 陽イオンおよび陰イオン交換クロマトグラフィー法 | |
| Chehraghi et al. | Purification of Monoclonal Antibodies Using Chromatographic Methods: Increasing Purity and Recovery | |
| Mountford et al. | Design, synthesis and evaluation of pyridine-based chromatographic adsorbents for antibody purification | |
| HK40109957A (zh) | 用於抗体药物缀合物的流通阳离子交换色谱纯化过程 | |
| Linke et al. | Process scale separation of an anti-CD22 immunotoxin charge variant | |
| AU2021209196A1 (en) | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond | |
| Hendricks et al. | Simplified strategy for developing purification processes for antibody-drug conjugates using cation-exchange chromatography in flow-through mode | |
| Akhtar et al. | Evaluation of the efficiency of protein A affinity chromatography to purify a monoclonal antibody for cancer treatment and its purity analysis | |
| KR20240049657A (ko) | 재조합 항체 단편을 정제하는 방법 | |
| Tanaka et al. | Elution Profiles of Antibody-Drug Conjugates in Preparative Chromatography | |
| AU2011282774B9 (en) | Method for purifying active polypeptides or immunoconjugates | |
| Withanage et al. | Purification of a Fc-Fusion Protein with [Bathophenathroline: metal] Complexes. Antibodies 2025, 14, 11 | |
| HK1193617A (en) | Cation and anion exchange chromatography method | |
| Tutor et al. | MULTIDIMENSIONAL CRUDE FEEDSTOCK PROFILING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241216 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241216 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250724 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250827 |